The Weekly Briefing
The Everhealth Weekly
Evidence-based intelligence for preventing chronic disease and extending healthspan.
Good morning,
This week’s evidence keeps circling one unglamorous idea: the interventions that actually prevent disease are rarely exotic — they’re specific. A cholesterol drug earns its place in people who’ve never had a heart attack. A weight-loss medication turns out to quiet a second problem no one prescribed it for. And the amount of strength training that buys you the most years is smaller than you’d guess, and stops paying out sooner. The theme is dose and fit: the right thing, for the right person, in the right amount.
— The Everhealth Institute team
This Week in the Evidence
A cholesterol drug proves itself in people who’ve never had a heart attack
In the VESALIUS-CV trial, adults at high risk but with no prior heart attack or stroke — all with existing atherosclerosis or diabetes and an LDL of at least 90 mg/dL — were randomized to the PCSK9 inhibitor evolocumab or placebo on top of usual care. Over a median 4.5 years, evolocumab lowered LDL by roughly 55% (to a median near 45 mg/dL) and cut major cardiovascular events — cardiac death, heart attack, or ischemic stroke — by 25%. It is the first time this drug class has shown that benefit in a true primary-prevention population.
Source: Evolocumab in Patients without a Previous MI or Stroke — NEJM (Nov 2025)
GLP-1 drugs linked to fewer alcohol-related hospital visits
Drawing on records from 30 US health systems, researchers emulated randomized trials comparing the newer GLP-1 drugs (semaglutide, tirzepatide) with older diabetes, obesity, and alcohol-use-disorder medications — all in adults who had alcohol use disorder plus diabetes or obesity. GLP-1 users had roughly 22–32% fewer alcohol-related hospital visits than those on older diabetes or obesity drugs, and — most striking — 63–65% fewer than patients taking medications currently approved for alcohol use disorder.
For strength training, the longevity “sweet spot” is about 90 minutes a week
Across three long-running Harvard cohorts, adults who did 90–119 minutes of strength training per week had a 13% lower risk of death from any cause, with larger reductions in cardiovascular (19%) and neurological (27%) mortality. Past roughly 120 minutes a week, the benefit flattened — more was not better. The lowest mortality of all belonged to people who combined resistance work with plenty of aerobic activity.
Source: British Journal of Sports Medicine, via ScienceDaily (June 2026)
The Long View
The Long View
The dose makes the medicine
There is a quiet pattern running through this week’s studies, and it isn’t the one the headlines will chase. A cholesterol drug works — but in a carefully bounded high-risk group, not everyone. A weight-loss medication may steady a craving — but we glimpsed it by watching who was already taking it, not by proving cause. Strength training extends life — but the benefit arrives near ninety minutes a week and then, stubbornly, stops climbing. In each case the useful knowledge is not “this works,” but “this much, for these people, to this degree.”
That is the real frontier of prevention, and it is less cinematic than the word “breakthrough” suggests. The science of healthspan is converging not on a single miracle but on dose, timing, and fit: the right intervention, in the right person, at the right intensity, begun early enough to matter. The five-hundred-year-old idea that “the dose makes the poison” has a preventive twin — the dose makes the medicine — and modern data keep proving it in new registers.
This reframing changes what a good clinician does. It makes the interesting question not “does this help?” but “how much, and for whom, and when?” A statin-class benefit that is real in someone with diabetes and rising plaque may be negligible in a low-risk forty-year-old. A movement prescription that saves lives at ninety minutes offers little extra at three hours. The skill is no longer knowing that an intervention is good; it’s calibrating it — reading an individual’s genomics, biomarkers, and biometrics closely enough to place them on the dose–response curve rather than at its average.
The temptation, always, is to over-read a promising signal — to turn “GLP-1 drugs may curb drinking” into a prescription before the randomized evidence exists. Precision prevention is the discipline of resisting that pull: measuring carefully, matching honestly, and holding an emerging finding as a hypothesis rather than a verdict. The clinicians and patients who master dose and fit — not just direction — will spend the next decade preventing disease that everyone else merely names. That is the whole project: not more medicine, but the right amount of it.
Do This Week
- 1Ask where you sit on the risk curve — before you need to. The cholesterol news matters most for people with diabetes or existing plaque whose LDL isn’t at goal. If that’s you, this is a good week to ask your clinician whether more aggressive lowering is warranted; if you’re low-risk, it may not be.
- 2Aim for about 90 minutes of strength work a week — and drop the guilt past two hours. Two or three short sessions covering the major muscle groups captures most of the longevity benefit. Beyond ~120 minutes, the data say you’re not buying much more.
- 3Pair the weights with aerobic movement. The lowest death rates belonged to people who did both. Think of resistance and cardio as two halves of one prescription, not competing hobbies.
- 4Treat exciting drug headlines as hypotheses, not instructions. The GLP-1-and-alcohol finding is intriguing, but it’s early and observational — not a reason to start a medication for that purpose. If you already take a GLP-1 and notice changes, that’s worth telling your clinician, not acting on alone.